What is the recommended treatment plan for hidradenitis suppurativa, including lifestyle modifications, topical and systemic antibiotics, biologic therapy, and surgical options?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Recommended Treatment Plan for Hidradenitis Suppurativa

For mild disease (Hurley stage I), start with topical clindamycin 1% solution combined with antiseptic cleansers; for moderate disease (Hurley stage II), use combination clindamycin 300 mg + rifampin 300 mg twice daily for 8-12 weeks; for severe disease (Hurley stage III), initiate adalimumab (the only FDA-approved biologic) while using antibiotics as adjunctive therapy, with surgical intervention for definitive management of chronic lesions. 1

Lifestyle Modifications

Weight loss and smoking cessation are critical first-line interventions that should be implemented immediately upon diagnosis. 2 While evidence for specific clothing recommendations is limited, loose-fitting cotton clothing may reduce friction-related flares, which 16% of patients report as a trigger. 3

Regarding personal care products:

  • Use antiseptic cleansers (chlorhexidine, benzoyl peroxide, or zinc pyrithione) based on expert consensus 1
  • Evidence does not support avoiding deodorants or antiperspirants despite anecdotal reports 3
  • Shaving and chemical depilatories show no clear association with disease worsening 3

Common pitfall: Insufficient evidence exists to recommend routine zinc or vitamin D supplementation despite some retrospective data showing benefit. 3

Topical and Intralesional Therapies

For Hurley stage I disease, topical clindamycin 1% solution is the only evidence-based topical antibiotic, demonstrating reduced pustules in a 12-week RCT, though it does not affect inflammatory nodules or abscesses. 1 Benzoyl peroxide should be added to reduce Staphylococcus aureus resistance development. 1

For acute flares:

  • Intralesional triamcinolone 10 mg/mL (0.2-2.0 mL) provides rapid pain relief within 1 day and reduces erythema, edema, and suppuration 1
  • Resorcinol 15% cream (keratolytic/antiseptic) reduces pain and abscess duration but causes frequent irritant dermatitis 1

Systemic Antibiotics

The antibiotic hierarchy based on evidence quality:

First-line (Moderate Disease):

Clindamycin 300 mg + rifampin 300 mg, both twice daily for 8-12 weeks, shows 71-93% response rates across 187 patients in systematic review. 1 This can be repeated intermittently as monotherapy in mild-to-moderate disease or as adjuvant in severe disease.

Second-line:

Tetracycline 500 mg twice daily demonstrated 30% reduction in abscesses, performing similarly to topical clindamycin. 1 However, doxycycline showed no independent benefit when combined with adalimumab in PIONEER studies. 1

Third-line (Bridge Therapy):

Moxifloxacin 400 mg daily + metronidazole 500 mg three times daily + rifampin 300 mg twice daily achieved complete responses in 6/6 Hurley stage I, 8/10 stage II, but only 2/12 stage III patients. 1 Critical caveat: Stop metronidazole at 6 weeks to avoid neurologic toxicity. This regimen is reserved as bridge to surgery or long-term therapy. 1

Important limitation: In advanced disease, antibiotics have lower response rates and increased recurrence, serving only an adjunctive role. 1

Biologic Therapy

Adalimumab is the only FDA-approved biologic for moderate-to-severe HS and should be initiated when antibiotics fail or for rapidly progressive disease. 2, 4 Recent expert consensus indicates that 81% of specialists prescribe antibiotics despite anticipating inadequate responses, and 77% support earlier biologic initiation in cases of persistent flares during antibiotic treatment. 5

Specific phenotypes warranting earlier biologic intervention:

  • Rapidly progressing disease
  • Extensive anatomical involvement
  • Persistent flares during antibiotic therapy
  • Significant comorbidities 5

Emerging evidence: Anti-IL-17A/A-F inhibitors are in clinical trials and may expand treatment options. 4, 6 JAK inhibitors, complement inhibitors, and IL-1 blockade are under investigation. 6

Surgical Options

Surgical intervention is essential for definitive management and should be considered adjunctive to medical therapy, particularly for refractory cases and scarring. 7

Acute Lesions:

Deroofing is superior to incision and drainage, with only 4-17% recurrence rates versus nearly 100% for simple drainage. 3 The technique involves probing abscesses/sinuses and removing overlying skin stepwise while leaving the base untreated, achieving 90% patient satisfaction. 3

Critical distinction: Incision and drainage provides only acute relief when other methods are unavailable and should be avoided when possible. 3 For large nonrecurrent abscesses, drainage can reduce inflammation before definitive surgery.

Chronic Lesions:

Wide excision and deroofing show equivalent effectiveness (approximately 24% recurrence) and are superior to drainage (100% recurrence). 3 Younger age and multiple operative sites increase recurrence risk. 3

CO₂ laser excision with marsupialization shows promise for chronic lesions. 3

Pain Management and Wound Care

Intralesional triamcinolone provides significant pain reduction within 24 hours for acute inflammatory lesions. 1 The algorithm should incorporate systematic pain assessment and management strategies, though specific protocols require individualization based on lesion burden and patient tolerance.

Treatment Algorithm by Hurley Stage

Hurley Stage I (mild):

  1. Antiseptic cleansers + topical clindamycin 1% with benzoyl peroxide
  2. If inadequate: Add tetracycline 500 mg twice daily
  3. Intralesional triamcinolone for acute flares
  4. Deroofing for persistent lesions

Hurley Stage II (moderate):

  1. Clindamycin 300 mg + rifampin 300 mg twice daily × 8-12 weeks
  2. If inadequate: Initiate adalimumab
  3. Surgical deroofing or excision for chronic lesions
  4. Continue topical therapies as adjunct

Hurley Stage III (severe):

  1. Adalimumab as primary therapy 1, 2
  2. Antibiotics (clindamycin/rifampin) as adjunctive therapy
  3. Consider triple antibiotic therapy (moxifloxacin/metronidazole/rifampin) as bridge
  4. Wide surgical excision for definitive management 3
  5. Medical optimization before surgery improves outcomes 8

Critical practice point: The 2019 North American guidelines mandate 10-12 weeks of antibiotics before biologics per licensing regulations 5, but 79% of experts favor short-term biologic therapy over antibiotics for early-stage HS with aggressive features. 5 This represents evolving practice patterns that may precede future guideline updates.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.